IL6 and cancer: Clinical conditions in CRC patients with high expression levels of those cytokines and/or pro-inflammatory cytokines such as IL-6 and IL-8 have been associated with drug resistance, distant metastasis, cancer recurrence, and a poor 5-year survival rate [72,73].